Table 3 Evaluation of bortezomib in combination with other therapies.
From: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
Type of therapy | Drug or agent | Cancer | References |
|---|---|---|---|
Chemotherapy | 5-Fluorouracil, cisplatin, paclitaxel, doxorubicin, cyclophosphamide | Breast, lung | Teicher et al [45], 1999 |
| Â | Melphalan, doxorubicin, dexamethasone | Multiple myeloma | Hideshima et al [15], 2001 Mitsiades et al [50], 2003 Ma et al [20], 2003 |
| Â | Topoisomerase inhibitor: irinotecan | Colon Pancreatic | Cusack et al [30], 2001 Shah et al [24], 2001 |
| Â | Gemcitabine | Pancreatic Bladder | Bold et al [48], 2001 Kamat et al [51], 2004 |
| Â | Pegylated liposomal doxorubicin | Breast | Small et al [52], 2004 |
| Â | Docetaxel | Pancreatic | Nawrocki et al [53], 2004 |
| Â | Temozolomide | Melanoma | Amiri et al [49], 2004 |
Radiation therapy | Â | Breast Colon Prostate | Teicher et al [45], 1999 Russo et al [16], 2001 Pervan et al [54], 2001 |
Immunotherapy | Daclizumab | Adult T-cell leukemia | Tan and Waldmann [19], 2002 |
Novel agents | TRAIL/Apo2L | Multiple myeloma, myeloid leukemia, renal | Mitsiades et al [55], 2001 Sayers et al [56], 2003 |
| Â | HSP90 inhibitor: 17-AAG | Breast | Mimnaugh et al [39], 2004 |
| Â | HDAC inhibitors: SAHA, sodium butyrate | CML, multiple myeloma, lung | Denlinger et al [40], 2004 Yu et al [57], 2003 Mitsiades et al [58], 2004 Denlinger et al [59], 2004 Pei et al [60], 2004 |
Transplantation | Allogeneic BMT | Leukemia | Sun et al [61], 2004 |